Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/hdi.12157 http://scihub22266oqcxt.onion/10.1111/hdi.12157 C4220040!4220040 !24620987     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24620987 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Hemodial+Int 2014 ; 18 (3 ): 641-9 Nephropedia Template TP {{tp|p=24620987 |t=2014. Anticoagulation, delivered dose and outcomes in CRRT: The program to improve care in acute renal disease (PICARD) |pdf=|usr=}}{{24620987 }} gab.com Text Anticoagulation, delivered dose and outcomes in CRRT: The program to improve care in acute renal disease (PICARD) JO: Hemodial Int http://www.kidney.de/pget.php?&tw=1&pmid=24620987 #FOAvip Delivered dialysis dose by continuous renal replacement therapies (CRRT) depends on circuit efficacy, which is influenced in part by the anticoagulation strategy. We evaluated the association of anticoagulation strategy used on solute clearance efficacy, circuit longevity, bleeding complications, and mortality. We analyzed data from 1740 sessions 24?h in length among 244 critically ill patients, with at least 48?h on CRRT. Regional citrate, heparin, or saline flushes was variably used to prevent or attenuate filter clotting. We calculated delivered dose using the standardized Kt/Vurea . We monitored filter efficacy by calculating effluent urea nitrogen/blood urea nitrogen ratios. Filter longevity was significantly higher with citrate (median 48, interquartile range [IQR] 20.3-75.0 hours) than with heparin (5.9, IQR 8.5-27.0 hours) or no anticoagulation (17.5, IQR 9.5-32 hours, P?<?0.0001). Delivered dose was highest in treatments where citrate was employed. Bleeding complications were similar across the three groups (P?=?0.25). Compared with no anticoagulation, odds of death was higher with the heparin use (odds ratio [OR] 1.82, 95% confidence interval [CI] 1.02-3.32; P?=?0.033), but not with citrate (OR 1.02 95% CI 0.54-1.96; P?=?0.53). Relative to heparin or no anticoagulation, the use of regional citrate for anticoagulation in CRRT was associated with significantly prolonged filter life and increased filter efficacy with respect to delivered dialysis dose. Rates of bleeding complications, transfusions, and mortality were similar across the three groups. While these and other data suggest that citrate anticoagulation may offer superior technical performance than heparin or no anticoagulation, adequately powered clinical trials comparing alternative anticoagulation strategies should be performed to evaluate overall safety and efficacy. Twit Text FOAVip Anticoagulation, delivered dose and outcomes in CRRT: The program to improve care in acute renal disease (PICARD) ????Hemodial Int http://www.kidney.de/pget.php?&tw=1&pmid=24620987 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24620987 #FOAvip English Wikipedia <ref>{{Cite pmid|24620987 }}</ref> Anticoagulation, delivered dose and outcomes in CRRT: The program to improve care in acute renal disease (PICARD) #MMPMID24620987 Claure-Del Granado R ; Macedo E ; Soroko S ; Kim Y ; Chertow GM ; Himmelfarb J ; Ikizler TA ; Paganini EP ; Mehta RL Hemodial Int 2014[Jul]; 18 (3 ): 641-9 PMID24620987 show ga Delivered dialysis dose by continuous renal replacement therapies (CRRT) depends on circuit efficacy, which is influenced in part by the anticoagulation strategy. We evaluated the association of anticoagulation strategy used on solute clearance efficacy, circuit longevity, bleeding complications, and mortality. We analyzed data from 1740 sessions 24?h in length among 244 critically ill patients, with at least 48?h on CRRT. Regional citrate, heparin, or saline flushes was variably used to prevent or attenuate filter clotting. We calculated delivered dose using the standardized Kt/Vurea . We monitored filter efficacy by calculating effluent urea nitrogen/blood urea nitrogen ratios. Filter longevity was significantly higher with citrate (median 48, interquartile range [IQR] 20.3-75.0 hours) than with heparin (5.9, IQR 8.5-27.0 hours) or no anticoagulation (17.5, IQR 9.5-32 hours, P? |Acute Disease [MESH] |Anticoagulants/*administration & dosage [MESH] |Female [MESH] |Heparin/*administration & dosage [MESH] |Humans [MESH] |Kidney Diseases/drug therapy/*therapy [MESH] |Male [MESH] |Middle Aged [MESH] |Renal Dialysis/*methods [MESH]Anticoagulation, delivered dose and outcomes in CRRT: The program to i(epmc).pdf DeepDyve Pubget Overpricing